EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Genetic variants, thrombocytopenia, and clinical phenotype of type 2B von Willebrand disease: a median 16-year follow-up study

Calvin B van Kwawegen, Ferdows Atiq, Dara Endenburg, Karin Fijnvandraat, Karin P M van Galen, Marjon H Cnossen, Saskia E M Schols, Marieke J H A Kruip, Waander L van Heerde, Joke de Meris, Johanna G van der Bom, Jeroen Eikenboom und 3 weitere

Journal of Thrombosis and Haemostasis · 2024

DOI: 10.1016/j.jtha.2024.08.028 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Calvin B van Kwawegen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Erasmus MC, University Medical Center Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Thrombocytopenia, Phenotype, von Willebrand Disease, Type 2, von Willebrand Factor. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CSL Behring LLC, Takeda Pharmaceuticals USA Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Type 2B von Willebrand disease (VWD) is a bleeding disorder caused by gain-of-function variants in the VWF gene. The laboratory and clinical phenotype of type 2B VWD is heterogeneous. OBJECTIVES: We investigated associations between genotype and phenotype over a median of 16 years follow-up in a large cohort of well-characterized patients. METHODS: We included 64 genetically confirmed type 2B VWD patients from the national multicenter "Willebrand in the Netherlands" study and retrospectively collected clinical and laboratory data from electronic patient records. We analyzed associations between genotype and thrombocytopenia, bleeding phenotype, and events leading to endothelial activation and von Willebrand factor (VWF) secretion, including surgery, desmopressin administration, pregnancy, and delivery. RESULTS: Thrombocytopenia manifested in 67.2% of patients, with varying occurrences between genetic variants (p.Arg1306Trp: 75.0%, p.Arg1308Cys: 58.3%). The most important determinant of thrombocytopenia was the p.Arg1306Trp VWF variant (odds ratio, 25.1). Platelet counts strongly varied over time and were continuously 500 mL estimated blood loss at delivery, occurred in 5 of 8 deliveries, despite prophylactic treatment with VWF concentrates. CONCLUSION: This study reveals a strong association between VWF variant p.Arg1306Trp and thrombocytopenia in type 2B VWD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThrombocytopeniaPhenotypevon Willebrand Disease, Type 2von Willebrand FactorHumansFemaleNetherlandsMaleAdultFollow-Up StudiesRetrospective StudiesPregnancyYoung AdultAdolescentMiddle AgedHemorrhagePlatelet CountTime FactorsGenetic VariationGenetic Predisposition to DiseaseChildRisk FactorsDeamino Arginine Vasopressin

Stichwörter der Autor:innen

desmopressingenotypepregnancythrombocytopeniavon Willebrand disease

Substanzen

von Willebrand FactorDeamino Arginine Vasopressin

Autor:innen und Institutionen

  • Department of Hematology, Erasmus MC, University Medical Center Rotterdam, The Netherlands.
  • Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Pediatric Hematology, Amsterdam, The Netherlands; Department of Plasma Proteins, Sanquin Research, Amsterdam, The Netherlands.
  • Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht, The Netherlands.
  • Department of Pediatric Hematology and Oncology, Erasmus MC Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Department of Hematology, Radboud University Medical Center, and Hemophilia Treatment Center Nijmegen-Eindhoven-Maastricht, Nijmegen, The Netherlands.
  • Department of Hematology, Radboud University Medical Center, and Hemophilia Treatment Center Nijmegen-Eindhoven-Maastricht, Nijmegen, The Netherlands; Enzyre, Nijmegen, The Netherlands.

Förderung

  • CSL Behring LLC
  • Takeda Pharmaceuticals USA Inc

Zitieren

APA

van Kwawegen, C. B., Atiq, F., Endenburg, D., Fijnvandraat, K., van Galen, K. P. M., Cnossen, M. H., Schols, S. E. M., Kruip, M. J. H. A., van Heerde, W. L., de Meris, J., van der Bom, J. G., Eikenboom, J., Meijer, K., Leebeek, F. W. G., & WiN study group (2024). Genetic variants, thrombocytopenia, and clinical phenotype of type 2B von Willebrand disease: a median 16-year follow-up study. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.08.028

Vancouver

van Kwawegen CB, Atiq F, Endenburg D, Fijnvandraat K, van Galen KPM, Cnossen MH, et al. Genetic variants, thrombocytopenia, and clinical phenotype of type 2B von Willebrand disease: a median 16-year follow-up study. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2024.08.028

BibTeX
@article{vanKwawegen2024,
  author = {van Kwawegen, Calvin B and Atiq, Ferdows and Endenburg, Dara and Fijnvandraat, Karin and van Galen, Karin P M and Cnossen, Marjon H and Schols, Saskia E M and Kruip, Marieke J H A and van Heerde, Waander L and de Meris, Joke and van der Bom, Johanna G and Eikenboom, Jeroen and Meijer, Karina and Leebeek, Frank W G and WiN study group, WiN study group},
  title = {Genetic variants, thrombocytopenia, and clinical phenotype of type 2B von Willebrand disease: a median 16-year follow-up study},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2024},
  doi = {10.1016/j.jtha.2024.08.028}
}
Kostenlos starten →